For the quarter ending 2026-03-31, BNGO made $6,687K in revenue. -$8,303K in net income. Net profit margin of -124.17%.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Total revenue | 6,687 | 7,951 | 7,367 | 6,733 |
| Product | 3,205 | 4,384 | 3,842 | 3,150 |
| Intangible assets and other long-lived assets impairment | - | 0* | 0 | 0 |
| Product And Service Other | 230 | 167 | 155 | 106 |
| Restructuring costs | - | 0* | 0 | 0 |
| Total cost of revenue | 3,435 | 4,551 | 3,997 | 3,256 |
| Research and development | 3,139 | 3,229 | 2,844 | 2,931 |
| Selling, general and administrative | 8,010 | 8,707 | 9,064 | 8,346 |
| Total operating expenses | 11,149 | 11,936 | 11,908 | 11,277 |
| Loss from operations | -7,897 | -8,536 | -8,538 | -7,800 |
| Interest income | 223 | 276 | 268 | 277 |
| Other income (expense) | -619 | 363 | -219 | 676 |
| Total other income (expense) | -396 | 639 | 49 | 953 |
| Loss before income taxes | -8,293 | -7,897 | -8,489 | -6,847 |
| Provision for income taxes | 10 | 36 | 14 | 10 |
| Net loss | -8,303 | -7,933 | -8,503 | -6,857 |
| Basic EPS | -0.76 | -1.457 | -1.59 | -1.99 |
| Diluted EPS | -0.76 | -1.457 | -1.59 | -1.99 |
| Basic Average Shares | 10,979,000 | 5,445,000* | 5,338,000 | 3,441,000 |
| Diluted Average Shares | 10,979,000 | 5,445,000* | 5,338,000 | 3,441,000 |
Bionano Genomics, Inc. (BNGO)
Bionano Genomics, Inc. (BNGO)